Archive
538 articles, sorted by publication time.
The deal moves generative drug design from a technology showcase into pipeline-sharing with a major pharmaceutical company, but the real test remains clinical and regulatory, not the algorithm itself.
From wound repair to weight loss, neurological symptoms, and sleep, some peptides are circulating rapidly through online care and compounding pharmacies; FDA July meeting documents show that scientific evidence and medication safety remain the hardest thresholds to clear.
The pharmaceutical industry is moving generative AI from documents and search tools toward the core of R&D workflows; it may shorten the time needed for candidate molecule design and clinical data organization, but medical value still depends on traceable data, rigorous validation, and evidence acceptable to regulators.
After platinum-based drugs fail, ovarian cancer treatment often enters a narrow path with limited options. Glenmark is moving its HER2-targeted ADC into late-stage clinical development; the real question is not whether the concept is novel, but whether it can produce evidence strong enough to change treatment sequencing in a difficult-to-treat population.
The FDA’s first clearance of a regulatory T-cell therapy to reduce the risk of chronic graft-versus-host disease extends the treatment goal of allogeneic stem cell transplantation from “winning against cancer” to “rebuilding immune order”; but with limited source information, the magnitude of benefit, eligible populations, and clinical implementation still need to be clarified through review documents and follow-up data.
The collaboration, worth up to about $600 million, is betting not only on whether generative AI can draw molecules, but on whether it can deliver clinically verifiable drug candidates under the development standards of a major pharmaceutical company.
In a market where treatment options for benign prostatic hyperplasia are mature but unmet needs remain, Jyong Biotech is bringing its plant-derived drug candidate before international pharmaceutical companies. The focus of this meeting is not just a natural-products story, but whether partners can be convinced that it is developable, reviewable, and scalable.
A therapy that could potentially become first-in-class is enough to bring a rare endocrine disease back into capital market view; but with limited data at this point, Septerna’s real test remains whether it can turn mechanistic promise into reproducible, reviewable clinical benefit.
As new drug development increasingly relies on precise targets and complex platforms, plant-derived medicines are still seeking their own modern place: they must translate traditional experience into clinical evidence that can be reviewed, mass-produced, and used as a basis for collaboration.
From platform demonstration to cell line development, VERAXA’s BiTAC cancer program is entering a stage closer to drug production; but while data remain limited, this step represents technical progress, not proof of efficacy.
The collaboration, worth up to $600 million, brings generative AI drug design back into the core R&D process of a major pharmaceutical company; the real test is not whether algorithms can propose molecules, but whether drug candidates can withstand clinical and regulatory scrutiny.
As candidate molecules move toward manufacturable medicines, cell line development is a narrow gate that new cancer therapies must pass before leaving the laboratory; VERAXA’s latest progress brings its BiTAC platform into the practical test of quality, consistency, and scale-up production.